- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Imbruvica® | PCI-32765
ibrutinib is an approved drug (FDA (2013), EMA (2014))
Compound class: Synthetic organic
Comment: Ibrutinib is a clinically used inhibitor of Bruton's tyrosine kinase. It was originally approved with breakthrough therapy designation through the FDA's accelerated approval program.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: ibrutinib
|No information available.|
|Summary of Clinical Use|
|Ibrutinib is approved to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of leukemia, especially patients with MCL who have received at least one prior therapy. In Feb 2014 ibrutinib was granted US FDA approval for treating chronic lymphocytic leukemia (CLL), as with MCL, this is only indicated for patients who have received at least one prior therapy. In February 2015, the US FDA expanded approval to include the treatment of Waldenström's macroglobulinemia (WM), which is a form of type of non-Hodgkin's lymphoma. Approval was granted based on the outcome of clinical trial NCT01614821 which indicated that the drug can offer a substantial improvement over contemporary therapies.
In August 2017, the FDA expanded approval to include treatment of chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy (e.g. first-line corticosteroid therapy). This approval followed results from clinical trial NCT02195869. The recommended dose of ibrutinib for cGVHD is 420 mg, orally once daily.
|Mechanism Of Action and Pharmacodynamic Effects|
|Bruton's tyrosine kinase (BTK) is a key mediator of critical B-cell pro-survival mechanisms, including regulation of B-cell apoptosis, cell adhesion, and lymphocyte migration and traffiking to lymphoid tissue. Ibrutinib inhibits BTK by covalently binding to cysteine-481 close to the ATP binding domain of the kinase. By inhibiting this kinase, ibrutinib promotes malignant B-cell apoptosis, inhibits proliferation and prevents these cells from responding to survival stimuli present in the microenvironment.|
|Peak plasma concentration (Tmax) is reached approximately 2 hours following oral dose and is independent of the size of the dose administered. Total exposure following oral dose is proportional to the dose administered .|
|Terminal half-life is unchanged in relation to the dose administered (7.8±3.6 hours with 420 mg per day and 8.1±3.4 hours with 840 mg per day) .|
|There is no evidence to suggest that the effectiveness of ibrutinib is altered in elderly patients. The effectiveness of ibrutinib in the pediatric population has not been assessed.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)